Cargando…
Critical appraisal of paroxetine for the treatment of vasomotor symptoms
BACKGROUND: Vasomotor symptoms (VMS), characterized by hot flashes and night sweats, are the most commonly reported symptoms associated with estrogen deficiency during menopause and occur in up to 70% of women. The goal of treatment is to reduce the frequency and severity of symptoms. Although hormo...
Autores principales: | Carroll, Dana G, Lisenby, Katelin M, Carter, Tracy L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476484/ https://www.ncbi.nlm.nih.gov/pubmed/26124682 http://dx.doi.org/10.2147/IJWH.S50804 |
Ejemplares similares
-
A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms
por: David, Paru S, et al.
Publicado: (2022) -
Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis
por: Rhodes, Joshua R., et al.
Publicado: (2023) -
Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause
por: Pinkerton, JoAnn V., et al.
Publicado: (2015) -
Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause
por: Portman, David J., et al.
Publicado: (2014) -
Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)